The medical lifecycle of a pharmaceutical drug is often depicted as a linear progression of discovery, clinical trial validation, widespread adoption, and eventual retirement when safer or more effective alternatives emerge. However, the reality of modern clinical practice is far more circular and resistant to change. When researchers investigate a widely prescribed medication and discover that it poses severe risks or offers diminishing returns for older demographics, a lengthy bureaucratic and cultural process begins. Yet, even after medical associations issue stringent warnings, federal agencies update safety labels, and expert panels explicitly advise against their use, millions of older Americans continue taking these drugs. This phenomenon, often described by healthcare professionals as medical inertia, highlights a profound systemic challenge in translating evolving clinical evidence into everyday bedside practice.
Theanatomy of this delay reveals a frustratingly slow machinery. Initially, clinical researchers publish findings indicating that a staple medication is less effective or riskier for geriatric populations than previously understood. Subsequent studies corroborate these outcomes, prompting medical associations to revise clinical practice guidelines. Influential gatekeepers, such as the American Geriatrics Society, may incorporate the medication into the Beers Criteria—a benchmark list of potentially inappropriate medications for older adults. For preventive therapies, independent expert panels like the U.S. Preventive Services Task Force issue formal cautions, while regulatory bodies such as the Food and Drug Administration introduce black box warnings detailing alarming side effects. Despite these robust interventions, retrospective analyses of national healthcare data years later frequently reveal that consumption rates have barely budged, or in some cases, actually increased. Medications, as geriatricians frequently observe, behave much like barnacles: they are exceptionally easy to attach to a treatment regimen, but remarkably difficult to remove.
Understanding Medical Inertia and Prescribing Habits
To comprehend why outdated prescribing patterns persist, one must examine the operational realities of modern medicine. Michael Steinman, a geriatrician at the University of California-San Francisco and co-director of the U.S. Deprescribing Research Network, points out that medical inertia stems partly from simple information overload. Practicing clinicians must manage an overwhelming volume of daily responsibilities and clinical guidelines, meaning that new scientific discoveries can take years to filter into everyday consciousness.
Beyond logistical delays, however, human behavior plays a powerful role. Clinicians and patients alike develop entrenched habits for treating chronic conditions. Finding novel, non-pharmacological, or alternative approaches requires time, cognitive effort, and specialized resources that are rarely in surplus during a standard clinical encounter. Consequently, it remains far easier to default to established routines. Recent empirical examinations of three distinct drug classes widely utilized by older Americans—benzodiazepines, routine antibiotics for common gastrointestinal issues, and over-the-counter aspirin for primary cardiovascular prevention—vividly illustrate the tenacity of these prescribing habits and the profound difficulty of reversing course.
The Persisting Hazards of Benzodiazepine Use
The scientific community first began sounding alarms regarding the perils of benzodiazepines more than two decades ago. Prescribed primarily for insomnia and anxiety, drugs within this class offer rapid symptom relief, making them immensely popular among both patients seeking comfort and physicians aiming to alleviate distress. However, as Mark Olfson, a psychiatrist and epidemiologist at Columbia University, notes, these medications carry severe physiological tolls for older adults.
Benzodiazepines—including widely recognized agents like Valium, Xanax, and Ativan, alongside related non-benzodiazepine sedative hypnotics commonly known as Z-drugs, such as Ambien and Lunesta—directly impair balance, motor coordination, and cognitive function. In geriatric populations, these impairments frequently translate into catastrophic falls, debilitating fractures, and motor vehicle accidents. Furthermore, when combined with opioid analgesics for pain management, benzodiazepines significantly elevate the risk of fatal respiratory depression and overdose. Extended consumption also fosters profound physical dependence, leading to severe withdrawal symptoms upon cessation.
Despite progressive warnings, recent evaluations of prescribing trends published in the Annals of Internal Medicine present a nuanced picture of progress followed by troubling stagnation. Olfson and his research team observed that among individuals aged 65 and older, the proportion filling benzodiazepine prescriptions dropped from approximately 14 percent in 2015 to 11.5 percent in 2024. Yet, this downward trajectory stalled abruptly around the onset of the COVID-19 pandemic. Alasingly, prescribed usage actually crept upward among the oldest demographic—those aged 75 and older—rising from 12 percent in 2020 to roughly 13 percent four years later. Concurrently, dispensing rates through long-term care facility pharmacies more than doubled, and roughly one-third of users remained on the medications for longer than six months, sharply amplifying their risk of dependency.
Public health experts emphasize that patients should never discontinue benzodiazepines abruptly or independently, as sudden withdrawal can trigger severe medical complications. Safe discontinuation demands a carefully supervised, gradual tapering process managed by a qualified medical professional over the course of many weeks.
The Overuse of Antibiotics in Uncomplicated Diverticulitis
A parallel pattern of entrenched clinical habituation surrounds the administration of antibiotics. For generations, standard medical doctrine dictated that acute diverticulitis—characterized by the inflammation or infection of small outpouchings in the colon wall—required immediate antibiotic intervention, typically utilizing fluoroquinolones like Cipro and Levaquin, or amoxicillin-clavulanate combinations such as Augmentin.
Jesse Sutton, a pharmacist and researcher at the Minneapolis Veterans Affairs healthcare system, describes the historical mindset as absolute. Because antibiotics are universally recognized as lifesaving marvels of modern medicine, the prevailing clinical intuition was simple: when in doubt, deploy them.
However, this paradigm shifted fundamentally in 2015, when the American Gastroenterological Association formally recommended against routinely prescribing antibiotics for uncomplicated diverticulitis, which constitutes the vast majority of clinical presentations. A cascade of professional medical societies subsequently aligned with this guidance. Rigorous clinical trials had previously demonstrated that for uncomplicated cases, antibiotics exerted virtually zero measurable effect on overall mortality, the necessity for surgical intervention, complication rates, or disease recurrence.
Despite the lack of clinical benefit, the heavy price of antimicrobial exposure remained entirely active. Antibiotic-related adverse drug events account for a substantial volume of emergency department visits each year, driven by acute gastrointestinal distress such as nausea, vomiting, and diarrhea. Moreover, unnecessary exposure heightens patient susceptibility to severe, opportunistic pathogens like Clostridioides difficile. On a macro level, rampant overuse accelerates global antimicrobial resistance, which the World Health Organization has designated as a top-tier global public health threat.
To measure the impact of these updated guidelines, Sutton and his colleagues analyzed treatment pathways across 70,000 patient visits spanning 120 Veterans Affairs facilities over a decade. The research team anticipated a marked reduction in antibiotic utilization for uncomplicated diverticulitis. Instead, their findings, published in the Annals of Internal Medicine, revealed that antibiotic prescriptions remained virtually universal, persisting in 97 percent of clinical encounters regardless of established guidelines. Patients presenting with these uncomplicated cases would have achieved equivalent clinical recovery through conservative supportive care, such as short-term analgesic management with acetaminophen and a temporary clear liquid diet.
This phenomenon of unindicated antibiotic prescribing extends to other common geriatric conditions, including asymptomatic bacteriuria in older adults—where routine urine tests frequently prompt unnecessary treatments—and upper respiratory tract infections that are viral rather than bacterial in origin. Health authorities encourage patients questioning these prescriptions to respectfully inquire about the underlying clinical rationale, reinforcing that pausing to evaluate necessity is a cornerstone of safe care.
Aspirin and the Pitfalls of Primary Cardiovascular Prevention
While prescription drugs require formal clinical authorization, over-the-counter medications present an entirely distinct set of challenges rooted in consumer self-management. Aspirin, accessible cheaply and without a prescription, exemplifies this dynamic. Millions of older Americans independently initiate daily aspirin regimens under the enduring assumption that it serves as a universal shield against cardiovascular disease.
Medical science fully supports daily low-dose aspirin for secondary prevention in individuals who have already experienced a myocardial infarction, ischemic stroke, or surgical interventions such as coronary stenting or bypass grafting. In these high-risk cohorts, clinical trials consistently demonstrate that the cardiovascular benefits outweigh the pharmacological risks.
However, the calculus shifts dramatically for primary prevention—individuals with no history of cardiovascular events. A major watershed occurred in 2019 when the American College of Cardiology and the American Heart Association formally recommended against routine aspirin use for primary prevention in adults aged 70 and older. The U.S. Preventive Services Task Force extended this caution further, advising against primary prevention aspirin initiation for individuals aged 60 and older. Extensive randomized clinical trials revealed minimal cardiovascular benefit for primary prevention groups, countered by a starkly elevated hazard of severe gastrointestinal bleeding. Timothy Anderson, an internist at the University of Pittsburgh and co-director of its Prescribing Wisely Lab, notes that as human physiology ages, mucosal vulnerability and bleeding risks escalate significantly, alongside rarer but catastrophic intracranial hemorrhages.
Recent data indicate that public health messaging is gradually penetrating the consumer landscape. A study co-authored by Anderson and published in JAMA tracked data from the National Health and Nutrition Examination Survey, revealing a substantial decline in primary prevention aspirin use among older adults between 2011 and 2023. Nevertheless, more than one-third of adults aged 70 and older continued the practice.
Experts emphasize critical clinical nuances: a carefully selected subgroup of older patients harboring exceptionally high cardiovascular risk profiles may still derive a net benefit from primary prevention aspirin. Conversely, emerging evidence suggests that older patients who abruptly discontinue long-term aspirin regimens without medical oversight may paradoxically face an elevated risk of subsequent cardiovascular events. Consequently, healthcare providers urge patients to initiate an explicit dialogue during routine check-ups to re-evaluate whether continuing aspirin remains appropriate. While patients often adopt these regimens out of a proactive desire to safeguard long-term vascular health, modern geriatric care offers far more targeted, sophisticated pharmacological strategies—such as advanced antihypertensive regimens and statin therapy—to manage cardiovascular risk without the severe bleeding liabilities associated with routine aspirin use.
Broader Implications and the Path Forward
The enduring presence of outdated and potentially inappropriate medications within geriatric healthcare underscores an urgent need for structural reform. Overcoming medical inertia requires a multi-pronged approach that extends far beyond publishing guidelines in academic journals. Healthcare systems must invest heavily in clinical decision-support tools embedded within electronic health records, active pharmacist-led medication reviews, and patient education initiatives designed to demystify complex pharmacological regimens.
Deprescribing—the supervised, systematic process of tapering or stopping medications when harms outweigh potential benefits—is steadily emerging as an essential subspecialty within geriatric medicine. By bridging the gap between cutting-edge clinical research and everyday bedside consultations, the medical community can better align treatment practices with the evolving needs of an aging population, ensuring that therapeutics remain a source of healing rather than a persistent hazard.
Related posts:
